
A dried leaf on a stem is positioned on the left side of the image, extending vertically. The leaf is dark brown and curled. The stem is thin and dark. The background is a light, textured surface with subtle yellow and brown tones, resembling aged paper or a natural material.

Viata fără alergii între vis și realitate

**Dr. Loredana Vasile
Medic primar alergologie și imunologie clinică**

Suferințele alergicului









Imunoterapie alergen specifică

- Administrare alergenului responsabil de simptomele anumitor patologii alergice
- Desensibilizare la alergen – inducerea toleranței
- 109 ani de SCIT
- 30 ani de SLIT



Indicații

- Rinita alergică
- Conjunctivita alergică
- Astmul alergic
- Alergia la Hymenoptere
- Dermatita atopică cu sensibilizare la aeroalergeni
- Alergia alimentară



Indicații

- boli alergice IgE mediate:
 - Acarienii din praful de casă
 - Polenuri de graminee, Betulacee, buruieni
 - Epitelii de animale: câine, pisică
 - Hymenoptere: viespe, albină, furnicile de foc
- IT cu mucegaiuri și alergeni nestandardizați (eficiență redusă sau nu foarte bine documentată)
- IT la alimente – dificultăți practice



Rinita/rinoconjunctivita alergică și astm

- Răspuns parțial sau insuficient la tratament și evitarea alergenului
- Efecte adverse importante ale medicației
- Evitarea tratamentului farmacologic pe termen lung
- Coexistența rinitei și a astmului
- Posibilitatea prevenției astmului la copil*
- Reducerea dezvoltării de noi sensibilizări*.**
- Reducerea costului medicației

* Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review D. Di Bona A. Plaia M. S. Leto-Barone Allergy 07 dec 2016

**Early Intervention is Important to Prevent Sensitization to New Allergens Tetsuya Terada* and Ryo Kawata Med Sci (Basel). 2018 Dec



Costuri directe

- Aparent prohibitiv
 - între 1400 și 2800 lei pe an / alergen
 - 4200 / 8400 lei pe cura minimă de 3 ani
- Este mult?

Costuri directe și indirecte ale bolilor

- Medicație pentru rinită, conjunctivită, astm pe 6-10 ani
- Măsuri de evicție: huse impermeabile, aspirator, dehumidificator, purificator
- Vizite la medici: medic de familie, ORL, pneumolog, alergolog
- Zile lipsă școală/muncă

Prospective clinical trials			
Ariano, 2006 ¹ Italy	Prospective, randomized, open-label, parallel-group trial SCIT + ST vs ST	30 adults with AR and/or asthma caused by <i>Parietaria</i> pollen SCIT + ST (N = 20) ST (N = 10)	<ul style="list-style-type: none"> ■ Costs reported in unspecified year (assume 2006) in USD ■ Mean annual per-patient cost difference between ST vs SCIT + ST = ST - SCIT + ST <ul style="list-style-type: none"> ● Year 1: \$104 (not significant) ● Year 2: -\$172 (not significant) ● Year 3: -\$581 (P < .0001) ● Year 4: -\$947 (P < .0001) ● Year 5: -\$952 (P < .0001) ● Year 6: -\$958 (P < .0001) <p>Negative results denote cost savings, and positive results denote cost outlay</p>
Omnes, 2007 ^{1b} France	Economic modeling study—decision-tree analysis based on literature survey and expert opinion SCIT + ST vs SLIT + ST vs ST	1000 hypothetical adult and child patients with AR who received either SCIT/SLIT (3-4 y) or ST over 7-8 y Model cast in terms of incremental cost per improved patient and incremental cost per asthma case avoided Direct costs: clinic visits, diagnosis, follow-up tests, drugs, SCIT; indirect costs included for adult model (productivity loss); hospitalizations were not included because considered rare	<ul style="list-style-type: none"> ■ Costs reported in 2003 Euros ■ Incremental cost-effectiveness ratio per additional improved patient (SCIT vs ST) <ul style="list-style-type: none"> ● \$362 (children-HDM); \$435 (children-pollen) ● \$232 (adults-HDM); \$748 (adults-pollen) ■ Incremental cost-effectiveness ratio per additional asthma case avoided for SCIT vs ST: <ul style="list-style-type: none"> ● \$604 (children-HDM); \$619 (children-pollen) ● \$407 (adults-HDM); \$1282 (adults-pollen)
Schadlich, 2000 ¹⁷ Germany	Economic modeling study SCIT vs ST	1000 hypothetical adults with AR receiving SCIT vs ST for 3 y and followed for 10 y	<ul style="list-style-type: none"> ■ Costs reported in 1997 Deutsche Mark ■ Break-even point (cumulative costs) reached between years 6 and 8 ■ Net savings of \$623 (payer) to \$1141 (societal) per patient over 10 y ■ 10-y incremental cost-effectiveness ratio (ICER) (payer) for SCIT vs ST per additional asthma case avoided: -\$3490 to -\$3904

1. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Meadows A, Kaambwa B, Novielli N, Huissoon A, J. Health Technol Assess. 2013
2. Assessing the cost-effectiveness of allergen immunotherapy in allergic rhinitis. Incorvaia C, Makrì E, Ridolo E. Am J Rhinol Allergy. 2014

Cine decide?



